Veritas In Silico

Veritas In Silico ROCE

The Return on Capital Employed (ROCE) of Veritas In Silico (130A.T) as of Oct 27, 2026 is -22.24 %. In the previous year, Return on Capital Employed (ROCE) was -9.63 % — a change of 130.88% (lower).

ROCE

-22.24 %

YoY

130.88%

Last updated:

In 2025, Veritas In Silico's return on capital employed (ROCE) was -22.24 %, a 130.88% increase from the -9.63 % ROCE in the previous year.

The Veritas In Silico ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2021
-13.99 JPY
Jan 1, 2022
-9.00 JPY
Jan 1, 2023
2.39 JPY
Jan 1, 2024
-9.63 JPY
Jan 1, 2025
-22.24 JPY
The Veritas In Silico ROCE history
YEARROCEYoY
-22.24 %+130.88%
-9.63 %-503.43%
2.39 %-126.52%
-9.00 %-35.61%
-13.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veritas In Silico Stock analysis

What does Veritas In Silico do? Veritas In Silico Inc generates revenue through its ibVIS platform, which provides small molecule drug discovery services targeting mRNA. The company collaborates with pharmaceutical companies on joint drug discovery research to develop mRNA-targeted small molecule drugs. Its primary customers are pharmaceutical companies seeking innovative drug discovery solutions. The business focuses on integrating digital technology, including in silico RNA structural analysis, into the pharmaceutical discovery process. The company's core product, the ibVIS platform, combines in silico RNA structural analysis with drug discovery technology to accelerate the development of small molecule drugs targeting mRNA. This platform is offered as a service to pharmaceutical partners, enabling them to leverage advanced digital tools for more efficient drug discovery. The revenue model is based on contractual agreements with pharmaceutical firms for joint research projects. Veritas In Silico Inc's business model centers on providing specialized technology services to the pharmaceutical industry. The company does not sell physical products but offers its platform as a service for drug discovery. Its target market consists of pharmaceutical companies interested in mRNA-targeted therapies, which represent a growing segment in pharmaceutical research and development. Veritas In Silico is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Veritas In Silico's Return on Capital Employed (ROCE)

Veritas In Silico's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Veritas In Silico's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Veritas In Silico's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Veritas In Silico’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Veritas In Silico stock

Return on Capital Employed (ROCE) of Veritas In Silico is -22.24 % in 2025.

Return on Capital Employed (ROCE) of Veritas In Silico changed from -9.63 % to -22.24 %, representing a 130.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Veritas In Silico since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Veritas In Silico with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Veritas In Silico

All Key Metrics — Veritas In Silico